|Bid||342.40 x 0|
|Ask||280.16 x 0|
|Day's Range||308.02 - 313.59|
|52 Week Range||184.00 - 313.59|
|Beta (5Y Monthly)||0.33|
|PE Ratio (TTM)||73.52|
|Earnings Date||Feb 12, 2020|
|Forward Dividend & Yield||2.91 (0.94%)|
|Ex-Dividend Date||Sep 10, 2019|
|1y Target Est||151.95|
Peer reviewed: ScienceProject funding: Australian Research Council, National Health and Medical Research Council, Cancer Council Victoria, the Victorian Cancer Agency and CSL LimitedThis study used in-vitro models
Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, will present at the 38th annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer and Managing Director Paul Perreault will present the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
Seqirus announced today results from a prospective, cluster-randomized trial led by a team of researchers from Brown University that showed FLUAD®, an adjuvanted trivalent influenza vaccine (aTIV), was more effective than standard non-adjuvanted trivalent influenza vaccine (TIV) in reducing the risk of all-cause hospitalizations, as well as hospitalization for influenza and pneumonia, in adults 65 years and older living in United States (U.S.) nursing homes during the 2016/17 influenza season.1 These findings were presented at the recent National Foundation for Infectious Diseases (NFID) 2019 Clinical Vaccinology Course (CVC), which took place in Washington, D.C.
Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. CIDP is a rare autoimmune disorder that affects the peripheral nerves and has the potential to cause significant disability.
KING OF PRUSSIA, Pa., Oct. 24, 2019 /PRNewswire/ -- Harvard Business Review (HBR) today named CSL Limited CEO and Managing Director Paul Perreault among the Top 100 Best Performing CEOs in the world for 2019. Unlike rankings that are based on subjective evaluations or short-term metrics, the CEO 100 list relies on objective performance measures over a chief executive's entire tenure, according to HBR. This is Perreault's first time on the CEO 100 at no. 83.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of CSL Limited and other ratings that are associated with the same analytical unit. "IMPORTANT NOTICE: MOODY'S RATINGS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
HOLLY SPRINGS, N.C. , Sept. 26, 2019 /PRNewswire/ -- Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, applauds the Administration for recognizing the urgency of ensuring Americans ...
SUMMIT, N.J. , Aug. 31, 2019 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in ...
SUMMIT, N.J. , Aug. 30, 2019 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today presented data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore from ...
SUMMIT, N.J. , Aug. 22, 2019 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced it will feature data in 3 presentations and 24 posters on the company's adjuvant and cell-based ...
SUMMIT, N.J., July 17, 2019 /PRNewswire/ -- CSL Limited today named Anjana Narain, a seasoned leader in vaccines and biopharmaceuticals, as Executive Vice President and General Manager of its Seqirus business, one of the world's largest influenza vaccines providers, effective 1 August. "In leading Seqirus, Anjana brings diverse, broad-based experience as a well-established global industry leader," said Paul Perreault, CSL CEO and Managing Director. "Anjana has focused on protecting public health throughout her career, which will be important in continuing to advance Seqirus' differentiated technologies and further grow its market reach.
SUMMIT, N.J. , July 15, 2019 /PRNewswire/ -- Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming 2019/20 U.S. influenza season Seqirus plans to distribute more ...
Novel real world evidence for AFSTYLA® and IDELVION® to be highlighted MELBOURNE, Australia , July 2, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the company will ...